Sedation – Pipeline Review, H2 2012

Sedation – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, ‘Sedation – Pipeline Review, H2 2012′, provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Sedation, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Sedation. Sedation – Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Sedation.
- A review of the Sedation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Sedation pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Sedation.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Sedation pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Sedation – Pipeline Review, H2 2012

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Sedation Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Sedation 7
Sedation Therapeutics under Development by Companies 9
Sedation Therapeutics under Investigation by Universities/Institutes 10
Late Stage Products 11
Comparative Analysis 11
Mid Clinical Stage Products 12
Comparative Analysis 12
Discovery and Pre-Clinical Stage Products 13
Comparative Analysis 13
Sedation Therapeutics - Products under Development by Companies 14
Sedation Therapeutics - Products under Investigation by Universities/Institutes 15
Companies Involved in Sedation Therapeutics Development 16
AstraZeneca PLC 16
AcelRx Pharmaceuticals, Inc. 17
PAION AG 18
Mayne Pharma Limited 19
Sedation - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Route of Administration 21
Assessment by Molecule Type 23
Drug Profiles 25
CNS-7056 - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
sufentanil + triazolam - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
zolpidem - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
propofol - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
dexmedetomidine hydrochloride - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Midazolam - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
PF0713 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
flumazenil - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Sedation Therapeutics - Drug Profile Updates 36
Sedation Therapeutics - Discontinued Products 38
Sedation Therapeutics - Dormant Products 39
Sedation - Product Development Milestones 40
Featured News & Press Releases 40
May 14, 2012: Ono Pharma Announces Phase II Study Results Of ONO-2745/CNS 7056 40
Oct 14, 2011: APP Pharmaceuticals Announces Increased Availability Of APP Diprivan And APP Propofol 1% 40
Jul 22, 2011: Orion Receives Positive CHMP Opinion For Dexdor 41
May 18, 2011: AcelRx Pharma Presents ARX-03 Clinical Study Results At 30th Annual Scientific Meeting Of American Pain Society 41
Nov 04, 2009: Paion Reports Positive Results Of Its Short Acting Anaesthetic/Sedative CNS 7056 In A Phase IIa Study In Upper GI Endoscopy 42
Apr 20, 2009: Paion Initiates Phase Ib Study Of The Anesthetic/Sedative CNS 7056 In Volunteers Undergoing Colonoscopy 43
Nov 19, 2008: Paion Announces Successful Completion Of Phase I Study With The Sedative/Anaesthetic CNS 7056 44
Appendix 45
Methodology 45
Coverage 45
Secondary Research 45
Primary Research 45
Expert Panel Validation 45
Contact Us 46
Disclaimer 46

List of Tables
Number of Products Under Development for Sedation, H2 2012 7
Products under Development for Sedation - Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 9
Number of Products under Investigation by Universities/Institutes, H2 2012 10
Comparative Analysis by Late Stage Development, H2 2012 11
Comparative Analysis by Mid Clinical Stage Development, H2 2012 12
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 13
Products under Development by Companies, H2 2012 14
Products under Investigation by Universities/Institutes, H2 2012 15
AstraZeneca PLC, H2 2012 16
AcelRx Pharmaceuticals, Inc., H2 2012 17
PAION AG, H2 2012 18
Mayne Pharma Limited, H2 2012 19
Assessment by Monotherapy Products, H2 2012 20
Assessment by Stage and Route of Administration, H2 2012 22
Assessment by Stage and Molecule Type, H2 2012 24
Sedation Therapeutics - Drug Profile Updates 36
Sedation Therapeutics - Discontinued Products 38
Sedation Therapeutics - Dormant Products 39

List of Figures
Number of Products under Development for Sedation, H2 2012 7
Products under Development for Sedation - Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Products under Investigation by Universities/Institutes, H2 2012 10
Late Stage Products, H2 2012 11
Mid Clinical Stage Products, H2 2012 12
Discovery and Pre-Clinical Stage Products, H2 2012 13
Assessment by Monotherapy Products, H2 2012 20
Assessment by Route of Administration, H2 2012 21
Assessment by Stage and Route of Administration, H2 2012 22
Assessment by Molecule Type, H2 2012 23
Assessment by Stage and Molecule Type, H2 2012 24

• Computed Tomography (CT) Scan Technology Important For Therapeutic & Diagnostic
  Various medical disciplines use several types of tests and scans for therapeutic and diagnostic purposes. Computed tomography is one of the common medical imaging procedures. Also known as CT scan, this technology uses computed X-rays to produce tomographic images of various body parts. This nondestructive process helps visualizing various interior features of the body, within [...]
• An Overview of Interactive Television with Benefits and Features
  Media convergence technology has reached to new heights. Interactive television or ITV is one of the popular forms of media convergence that adds data services to the conventional television sets. In simple language, interactive TV is the television that the users can interact with and change its appearance as per their own preferences. This feature [...]
• What is Home Healthcare and How to Find Suitable Services ?
  Old age soon takes its toll on the abilities of taking care of your personal and healthcare needs. The number of senior citizens requiring assistance for healthcare is significantly rising. Not all of them are able to seek help from their loved ones. Elderly, who are not able to receive personal attention from their relatives [...]
• Why Global Positioning Systems (GPS) Devices are So Popular ?
  Global positioning system or GPS is a popular technology to have become an inseparable part of many gadgets used on daily basis. GPS is an innovative satellite navigation system based on space. It helps in gathering invaluable and essential information about location, time and weather conditions. Global positioning system also provides critical information to various [...]
• Five Tips to Start a Successful Children’s Book Publishing Business
  Parents across the globe have been telling bedtime stories to their children since the beginning of time. Children’s book is possibly the best tool that they have. Children’s book publishing is a great business to start with. Whether you are aiming to start a new business or are working for an established child’s book publisher, [...]

• Commercial Aircraft Market Analysis and 2023 Forecasts

London, May 16th, 2013 – The global commercial aircraft sector is expected to experience slow and stable growth during the forecast period (2013-2023). According to Boeing’s estimates, airline companies around the world are expected to procure approximately 34000 airplanes during …

• Belgian Defense Industry Worth US$3.1 Billion By 2018

London, May 14th, 2013 – Austerity measures and focus on reducing public debt are expected to stabilize the Belgian defense budget at US$3 billion at the end of the forecast period (2014-18). The country’s defense budget, which values US$3.6 billion …

• Wealth Management Models Industry Analysis & 2020 Forecasts

Wealth management is one of the most promising segments of the global financial services sector due to the emerging markets in Asia and Latin America. However, downside risks have intensified due to financial crises, volatility in capital markets, the movement …

• Global Polyol / Sorbitol Market: China HFCS Research Reports

RnR Market Research adds new market research reports on global sorbitol / polyol / glucitol market and China HFCS industry to its store.   A new report entitled “Global Sorbitol (Glucitol) Market Report & Forecast: Market Size, Share, Growth, Production …

• Cystic Fibrosis Market Analysis and 2017 Forecasts

New Disease-Modifying, Personalized Cystic Fibrosis Treatment, Starting a Trend in Drug Development   Disease-modifying treatments are becoming a reality for Cystic Fibrosis (CF) sufferers, potentially transforming this life-threatening condition into a manageable one, according to new analysis.   The new …

Croatia Pharmaceuticals and Healthcare Report Q3 2013

"......environment to domestic and international drugmakers, but we believe EU accession will ease the regulatory burden as legislation is harmonised with EU norms. In 2013 the economy is expected to post weak growth in anticipation of capital inflows from ......"

Japan Pharmaceuticals and Healthcare Report Q3 2013

"......firms will continue to expand overseas (especially in emerging markets) in order to maintain revenue growth. Headline Expenditure Projections Pharmaceuticals: JPY10,358bn (US$129.7) in 2012 to JPY10,823bn (US$118.9bn) in 2013; +4.5% in local c......"

Pakistan Pharmaceuticals and Healthcare Report Q3 2013

"......cades - continuing to limit revenue earning opportunities for companies whose product portfolios contain medicines for the treatment of long-term diseases. Headline Expenditure Projections Pharmaceuticals: PKR189.21bn (US$2.03bn) in 2012 to PR......"

Sudan and South Sudan Pharmaceuticals and Healthcare Report Q3 2013

"...... potential of the pharmaceutical industry. Headline Expenditure Projections Pharmaceuticals: SDG1.92bn (US$540mn) in 2012 to SDG2.38bn (US$510mn) in 2013; +24.0% in local currency terms with a contraction of -6.8% in US dollar terms. Forecast ......"

CompetitiveWatch Nucleic Acid Testing: Strategic Profiles of Leading Suppliers

"......nd emerging suppliers of nucleic acid testing products, including their sales, product portfolios, marketing tactics, technological know-how, new products in R&D, collaborative arrangements and business strategies......."